Canopy Growth Corporation Reports Third Quarter Fiscal 2018 Financial Results: Focussed on Execution

Record quarterly revenue of $21.7 million highest ever reported in Canadian cannabis sector driven by strong domestic and international sales

Record Germany quarterly sales of $1 million, all from domestic Canadian production

Year-over-year registered patient growth of 138% and revenue growth of 123%

Weighted average cost per gramto point of harvest decreased 18% sequentially quarter over quarter to $0.59 per gram, sixth consecutive quarter below $1 per gram; weighted average cost per gram before shipping and fulfillment decreased 18% sequentially quarter over quarter to $1.03 per gram

Only cannabis company to secure multi-year supply agreements with four provincial entities; multi-year commitments from Canopy totaling up to 25,000 kilograms per year

Secured four retail license allocations in Newfoundland and Labrador, locations represent first announced privately owned and operated legal cannabis retail locations in Canada.

Raised $245 million in landmark deal with Fortune 500 company Constellation Brands and subsequent $201 millionbought deal financing including the first co-led by a major bank, BMO Capital Markets

International production licenses announced in Denmark and Jamaica (provisional), bringing number of global licensed facilities to 102

Approximately $400 million cash on hand to fund domestic and global expansion

Canopy Growth Corporation (TSX: WEED) (“Canopy Growth” or “the Company”) today released its consolidated financial results for the third quarter ended December 31, 2017. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

“The Company’s record revenues in the quarter were driven by a significant increase in domestic sales across all product formats as well as sales in the German medical market, which is beginning to show impressive growth,” said Bruce Linton, Chairman & CEO. “Success in future global medical markets and the recreational cannabis market in Canada will depend not only on capacity, but on strong execution and securing supply agreements with the provinces today.  I believe our success on both these fronts is evident as you look at our accomplishments this past quarter.”

Added Linton, “With the sector’s largest inventory of diversified, high quality cannabis products, demonstrated distribution capabilities, robust IT infrastructure, a vast production footprint, investments in seven provinces across the country and a proven record of leadership and execution, we are now excelling into the anticipated recreational sector with unparalleled opportunity. With millions of square feet of production expansion underway across the country and around the world, as well as capacity offtake from our expanding roster of CraftGrow partners and through Canopy Rivers Corporation, we will ensure a sufficient and timely flow of supply to serve our line-up of unparalleled premium brands.”

Third Quarter 2018 Highlights

Q3 2018

Q2 2018

% Change

Q3 2017

% Change

Active registered patients

69,000

63,000

10%

29,000

138%

Kilograms and kilogram equivalents sold

2,330

2,020

15%

1,245

87%

Kilograms harvested

7,961

4,167

91%

5,264

51%

Inventory & Biological Assets (millions)

$108

$97

11%

$56

93%

Revenues (millions)

$21.7

$17.6

23%

$9.8

123%

Average selling price per gram

$8.30

$7.99

4%

$7.36

13%

Cost per gram to point of harvest 1

$0.59

$0.72

-18%

$0.87

-32%

Cost per gram before shipping and fullfillment 1

$1.03

$1.25

-18%

$1.70

-39%

Cash and Cash Equivalents (millions)2

$238

$108

121%

$93

156%

1) Weighted average cost per gram

2) Prior to subsequent $201 million gross proceeds raised in the bought deal closed February 7, 2018 and $26 million gross proceeds raised by Canopy Rivers in a private placement that closed on January 10, 2018 

 

  • First producer to sign separate multi-year cannabis supply Memorandum of Understanding (“MOU”) with the provinces of New Brunswick and Newfoundland & Labrador representing a combined total of up to 12,000 kilograms/year
  • Canopy Growth entered into a ground breaking strategic relationship with Fortune 500 global beverage leader Constellation Brands (“Constellation”). As part of the agreement, an affiliate of Constellation invested approximately $245 million in Canopy Growth in exchange for 9.9% equity and warrants in the Company and the parties have agreed to collaborate on new product development
  • Record third quarter revenue was $21.7 million, a 123% increase over the third quarter ended December 31, 2016when revenue totaled $9.8 million
  • Sold a record 2,330 kilograms and kilogram equivalents at an average sales price of $8.30 per gram, representing an increase of 87% and 13%, respectively over third quarter fiscal 2017
  • Oil sales, including softgel capsules, accounted for 23% of third quarter product revenue compared to 13% in the prior year period. Oil sales in the third quarter accounted for 2,132 litres (or approximately 262 kilogram equivalents) of the total kilogram and kilogram equivalents sold compared to 1,157 litres (or approximately 116 kilogram equivalents) of the total kilogram and kilogram equivalents sold in the comparison period last year
  • Net earnings in the quarter of fiscal 2018 of $11.0 million, or $0.01 per basic and diluted share
  • Inventory and biological assets valued at a record $108.3 million, inventories are continuing to be scaled to meet management’s expectation of market demands, including the legalized recreational market expected later in calendar 2018
  • Established joint business operations with large scale greenhouse operators in British Columbia and Quebec to retrofit upwards of 3.7 million sq. ft. of modern high-tech greenhouses
  • $237.7 million in cash and cash equivalents at quarter end prior to the addition of net proceeds of $192.5 million from bought deal that closed on February 7, 2018 and proceeds of Canopy Rivers private placement, net of $5.1 millioninvestment by Canopy Growth, of $20.0 million that closed on January 10, 2018

Subsequent to Third Quarter 2018

  • Closed a bought deal financing co-led by GMP Securities L.P. and BMO Capital Markets on February 7, 2018 that raised aggregate gross proceeds of $200.7 million. This financing marked the first equity deal in the cannabis sector co-led by a major Canadian chartered bank
  • Signed multi-year cannabis supply MOU with the province of Prince Edward Island for up to 1,000 kilograms/year
  • Signed letter of intent with the Société des alcools du Québec’s (“SAQ”) to provide the Quebec market with 12,000 kilos of high-quality cannabis annually
  • On January 10, 2018, Canopy Growth announced that its subsidiary, Canopy Rivers, closed a non-brokered private placement offering of 23,636,363 Class B common shares (the “Shares”) at a price of $1.10 per Share. Pursuant to the offering, Canopy Rivers raised aggregate gross proceeds of approximately $26 million. The Company subscribed for 4,673,938 Shares for approximately $5.1 million

Third Quarter Fiscal 2018 Revenue Review

Revenue for the third quarter fiscal 2018 was a record $21.7 million, representing an increase of 123% over the prior year’s quarter in which revenue was $9.8 million.  In the three months ended December 31, 2017 and 2016, oils, including the Company’s Softgel capsules, accounted for 23% and 13%, respectively, of the product revenue for each period.

Revenue in the nine months ended December 31, 2017 totaled $55.1 million more than double as compared to $25.2 million in the same period last year.  Revenues in the nine months ended December 31, 2017 already equal 138% of revenue generated in the twelve months ended March 31, 2017.

Third Quarter Fiscal 2018 Product Sales Review

During the third quarter of fiscal 2018, Canopy Growth sold 2,330 kilograms and kilogram equivalents at an average price of $8.30 per gram, up from 1,245 kilograms and kilogram equivalents at an average price of $7.36 per gram during the prior year period. The higher average price was due to primarily to the improved mix of oil products, including oil-based Softgel capsules and higher selling price of medical cannabis sold in Germany by wholly-owned subsidiary Spektrum Cannabis GmbH (“Spektrum Cannabis”).

Oil sales, including gel caps, accounted for 23% of third quarter product revenue (reported revenue net of merchandise revenue, clinic revenue and shipping fees). Oil sales in the third quarter accounted for 2,132 litres (or approximately 262 kilogram equivalents) of the kilogram and kilogram equivalents sold.  Spektrum Cannabis sold 78 kilograms in Germany, all sourced from Canadian domestic production, at an average price of $12.61 per gram.

Year-to-date, the Company has sold 6,198 kilograms and kilogram equivalents at an average price of $8.11 per gram compared to 3,399 kilograms at an average price of $7.12 per gram in the nine months ended December 31, 2016, representing an increase of 82% and 14%, respectively.

Third Quarter Fiscal 2018 Weighted Average Cost per Gram (Non-GAAP measure) 1

Weighted Average Cost Gram Information

Three Months Ended

December 31,

2017

September 30,

2017

June 30,

2017

March 31,

2017

December 31,

2016

Cost per Gram to Harvest

$

0.59

$

0.72

$

0.76

$

0.86

$

0.87

Post Harvest Cost per Gram

$

0.44

$

0.53

$

0.51

$

0.60

$

0.54

Cost per Gram before shipping and fulfilment

$

1.03

$

1.25

$

1.27

$

1.46

$

1.41

Cost per Gram for Shipping and Fulfilment

$

1.50

$

1.48

$

1.50

$

1.44

$

1.17

Weighted Average Cost per Gram

$

2.53

$

2.73

$

2.77

$

2.90

$

2.58

The Company continues to make successive operating improvements in production and post-harvest activities through scaling and investments made to achieve competitive cost leadership within the industry and may see further optimization as increasing percentages of each facility are brought online and efficiencies are fully realized.   The shipping and fulfilment costs include Canopy’s premium brand packaging, a differentiator to support the Company’s brand category positioning.

Third Quarter Fiscal 2018 Gross Margin Summary (Non-GAAP measure)3

The third quarter Fiscal 2018 gross margin before the fair value effects of the IFRS accounting for biological assets and inventory was $12.5 million or 58% of sales, as compared to $6.2 million or 64% of sales in the third quarter of last year. The lower gross margin percentage was due primarily to the impact of cash operating costs of subsidiaries not yet cultivating or selling cannabis. Excluding the costs associated with non-cultivating subsidiaries totaling $2.9 million, the gross margin before the fair value impacts in cost of sales would have been $15.5 million or 71% of sales.

Third Quarter Fiscal 2018 Operating Expense Summary

Management believes the ongoing investment in building the Company’s significant and diversified production platform, world-leading brands, unparalleled international reach, and iconic partnerships, all of which directly impacted profitability during the current period, is a prudent long-term investment to strengthen the Company’s global leadership position heading into next year.

Sales and marketing expenses in the third quarter fiscal 2018 were $9.4 million, or 43% of revenue. In comparison, Sales and marketing expenses were $3.8 million, or 39% of revenue in the same period last year.

General and Administrative (“G&A”) expenses in the third quarter fiscal 2018 were $11.1 million, or 51% of revenue.  In comparison, G&A expenses were $4.0 million, 41% of revenue, in the three months ended December 31, 2017.

Third Quarter Fiscal 2018 Adjusted EBITDA Summary (Non-GAAP measure)4

Adjusted EBITDA in the third quarter fiscal 2018 amounted to a loss of $7.1 million compared to a loss of $1.4 million in the same period last year.

The Adjusted EBITDA is reconciled and explained in the Management’s Discussion & Analysis under “Adjusted EBITDA (Non-GAAP Measure)” a copy of which has been filed today on www.sedar.com. The Adjusted EBITDA is reconciled in a table elsewhere in this press release.

Third Quarter Fiscal 2018 Earnings Summary

Net earnings in the third quarter of fiscal 2018 amounted to $11.0 million, or $0.01 per basic and diluted share, including the net non-cash fair value effects of the IFRS accounting for biological assets and inventory which combined to a gain of $6.5 million, fair value changes in financial assets amounting to $35.9 million and a gain on the partial disposal of Agripharm of $8.8 million, partially offset by non-cash share-based compensation expense and depreciation.   In the comparative period last year, the net income of $3.0 million, or $0.03 per basic share and $0.02 per diluted share including net non-cash effects of the IFRS accounting for biological assets and inventory which combined to a net gain of $10.7 million.

Third Quarter Fiscal 2018 Balance Sheet Highlights

At December 31, 2017, the Company’s cash and cash equivalents totaled $237.7 million, representing an increase of $135.9 million from March 31, 2017.

Inventory at December 31, 2017 amounted to $93.2 million (March 31, 2017 – $46.0 million) and biological assets amounted to $15.1 million (March 31, 2017 – $14.7 million), together totaling $108.3 million (March 31, 2017 – $60.7 million).  Inventories are continuing to be scaled to meet management’s expectation of market demands, including the legalized recreational market expected later in calendar 2018.

At December 31, 2017, the Company held 16,837 kilograms of dry cannabis and 5,919 litres of cannabis oils, ranging from concentrated resins, or refined oil, to finished oil. Included in the dry cannabis quantities was 2,606 kilograms available for sale in the Company’s online stores and 6,059 kilograms in process of finishing or awaiting approval for sale and 8,172 kilograms of extract-grade cannabis held for conversion to saleable oils and capsules.

The Unaudited Condensed Interim Consolidated Financial Statements and Management’s Discussion and Analysis documents for the three months ended December 31, 2017 have been filed with SEDAR and are available on www.sedar.com. The basis of financial reporting in the Unaudited Condensed Interim Consolidated Financial Statements and Management’s Discussion and Analysis documents is in thousands of Canadian dollars, unless otherwise indicated.

Note 1: The Weighted Average Cost Per Gram is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The definition of this term can be found in the Management’s Discussion & Analysis under Weighted Average Cost Per Gram (Non-GAAP measure), a copy of which has been filed today on www.sedar.com.

Note 2: Includes 40% owned Agripharm for which Canopy Growth has an off-take arrangement for between 75%-100% of their production.

Note 3: The Gross margin before the fair value effects of the IFRS accounting for biological assets and inventory is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.  The definition of this term can be found in the Management’s Discussion & Analysis under GROSS MARGIN (Non-GAAP measure), a copy of which has been filed today on www.sedar.com.

Note 4: The Adjusted EBITDA is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Adjusted EBITDA is reconciled and explained in the Management’s Discussion & Analysis under “Adjusted EBITDA (Non-GAAP Measure)”, a copy of which has been filed today on www.sedar.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation and its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

UNAUDITED

December 31,

March 31,

(Expressed in CDN $000’s)

2017

2017

Assets

Current assets

Cash and cash equivalents

$

237,708

$

101,800

Restricted short-term investments

668

550

Amounts receivable

9,075

5,815

Biological assets

15,075

14,725

Inventory

93,243

45,981

Prepaid expenses and other assets

18,479

3,735

374,248

172,606

Assets classified as held for sale

6,180

374,248

178,786

Property, plant and equipment

153,982

96,270

Deposits on property, plant and equipment

23,160

Other assets

1,932

Investments in associates

66,395

Other financial assets

75,224

24,030

Intangible assets

127,861

162,263

Goodwill

272,346

241,371

$

1,095,148

$

702,720

Liabilities

Current liabilities

Accounts payable and accrued liabilities

$

25,099

$

15,386

Deferred revenue

725

588

Current portion of long-term debt

1,499

1,691

Other liabilities

1,914

29,237

17,665

Long-term debt

7,294

8,639

Deferred tax liability

38,759

35,924

Other long-term liabilities

766

75,290

62,994

Shareholders’ equity

Share capital

866,550

621,541

Other reserves

117,833

23,415

Accumulated other comprehensive income

17,196

16,098

Deficit

(30,105)

(21,296)

Equity attributable to Canopy Growth Corporation

971,474

639,758

Non-controlling interests

48,384

(32)

Total equity

1,019,858

639,726

$

1,095,148

$

702,720

CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2017 AND 2016

Three months ended

Nine months ended

UNAUDITED

December 31,

December 31,

December 31,

December 31,

(Expressed in CDN $000’s except share amounts)

2017

2016

2017

2016

Revenue

$

21,700

$

9,752

$

55,142

$

25,234

Inventory production costs expensed to cost of sales

9,166

3,511

23,501

9,690

Gross margin before the undernoted

12,534

6,241

31,641

15,544

Fair value changes in biological assets included in inventory sold and other inventory charges

23,692

4,983

46,339

12,332

Unrealized gain on changes in fair value of biological assets

(29,728)

(15,685)

(81,713)

(33,003)

Gross margin

18,570

16,943

67,015

(20,671)

Sales and marketing

9,409

3,780

23,452

8,850

Research and development

287

439

914

1,345

General and administration

11,050

4,043

26,936

10,924

Acquisition-related costs

790

1,383

2,491

1,975

Share-based compensation expense

8,965

1,497

17,708

3,345

Share-based compensation expense related to acquisition milestones

8,914

11,228

Depreciation and amortization

5,187

1,048

15,535

2,943

Operating expenses

44,602

12,190

98,264

29,382

(Loss) income from operations

(26,032)

4,753

(31,249)

6,833

Share of loss in equity investments

(170)

(50)

Other expense, net

(33)

(181)

(39)

(270)

Fair value changes on financial assets

35,854

32,500

Gain on disposal of consolidated entity

8,820

8,820

Increase in fair value of acquisition consideration related liabilities

(895)

(1,193)

Other income (expenses)

44,641

(1,076)

41,111

(1,513)

Income before income taxes

18,609

3,677

9,862

5,320

Income tax recovery (expense)

(7,595)

(701)

(9,635)

(863)

Net income

$

11,014

$

2,976

$

227

$

4,457

Net income (loss) attributable to:

Canopy Growth Corporation

$

1,583

$

2,992

$

(8,809)

$

4,473

Non-controlling interests

9,431

(16)

9,036

(16)

$

11,014

$

2,976

$

227

$

4,457

Earnings per share, basic

Net income (loss) per share:

$

0.01

$

0.03

$

(0.05)

$

0.04

Weighted average number of outstanding common shares:

182,029,481

116,813,261

171,075,324

109,725,439

Earnings per share, diluted

Net income (loss) per share:

$

0.01

$

0.02

$

(0.05)

$

0.04

Weighted average number of outstanding common shares:

194,739,044

123,034,872

171,075,324

114,094,787

CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED DECEMBER 31, 2017 AND 2016

Three months ended

Nine months ended

UNAUDITED

December 31,

December 31,

December 31,

December 31,

(Expressed in CDN $000’s)

2017

2016

2017

2016

Net inflow (outflow) of cash related to the following activities:

Operating

Net income

$

11,014

$

2,976

$

227

$

4,457

Adjustments for:

Depreciation of property, plant and equipment

2,324

974

6,360

2,721

Amortization of intangible assets

2,863

74

9,175

222

Share of loss in equity investments

170

50

Fair value changes in biological assets included in inventory sold and other inventory charges

23,692

4,983

46,339

12,332

Unrealized gain on changes in fair value of biological assets

(29,728)

(15,685)

(81,713)

(33,003)

Share-based compensation

19,015

2,115

30,249

4,347

Contingent consideration provision

527

527

Loss on disposal of property, plant and equipment

385

218

553

218

Other assets

(1,932)

(1,932)

Fair value changes on financial assets

(35,506)

(32,152)

Gain on disposal of consolidated entity

(8,820)

(8,820)

Income tax expense

7,595

701

9,635

863

Increase in fair value of acquisition consideration related liabilities

895

1,193

Changes in non-cash operating working capital items

(12,625)

(218)

(22,686)

(5,311)

Net cash used in operating activities

(21,723)

(2,440)

(44,595)

(11,384)

Investing

Purchases and deposits of property, plant and equipment and assets in process

(60,581)

(7,972)

(86,107)

(16,700)

Purchases of intangible assets and intangibles in process

(751)

(1,033)

Proceeds on disposals of property and equipment

37

75

37

Purchases of restricted investments

(118)

Proceeds on assets classified as held for sale

7,000

Investments in affiliates

(12,650)

(18,824)

Indirect investments through Canopy Rivers

(19,257)

(27,732)

Net cash outflow on acquisition of subsidiaries

(3,241)

(783)

(3,600)

(783)

Net cash used in investing activities

(96,480)

(8,718)

(130,339)

(17,446)

Financing

Proceeds from issuance of common shares

244,990

60,017

269,990

106,026

Proceeds from issuance of shares by Canopy Rivers, net of share issue costs of $1,568

35,113

Proceeds from exercise of stock options

4,109

2,329

7,544

3,457

Proceeds from exercise of warrants

154

681

126

Issuance of long-term debt

3,500

Payment of share issue costs

(1,166)

(3,790)

(1,345)

(6,820)

Increase in finance lease obligations

260

Repayment of long-term debt

(387)

(273)

(1,141)

(612)

Net cash provided by financing activities

247,700

58,283

310,842

105,937

Net cash inflow

129,497

47,125

135,908

77,107

Cash and cash equivalents, beginning of year

108,211

45,379

101,800

15,397

Cash and cash equivalents, end of period

$

237,708

$

92,504

$

237,708

$

92,504

CANOPY GROWTH CORPORATION

Adjusted EBITDA1 Non-GAAP Measure

Three Months Ended

Nine Months Ended

(In CDN$000’s)

December 31,

2017

December 31,

2016

December 31,

2017

December 31,

2016

Adjusted EBITDA1 Reconciliation

(Loss) income from operations – as reported

$

(26,032)

$

4,753

$

(31,249)

$

6,833

IFRS non-cash accounting related to biological assets and inventory

Fair value changes in biological assets included in inventory sold and other inventory charges

23,692

4,983

46,339

12,332

Unrealized gain on changes in fair value of biological assets

(29,728)

(15,685)

(81,713)

(33,003)

(6,036)

(10,702)

(35,374)

(20,671)

Share-based compensation expense (per statement of cash flows)2

19,015

2,115

30,249

4,347

Acquisition Costs

790

1,383

2,491

1,975

Depreciation and amortization

5,187

1,048

15,535

2,943

24,992

4,546

48,275

9,265

Adjusted EBITDA

$

(7,076)

$

(1,403)

$

(18,348)

$

(4,573)

1 – Adjusted EBITDA is Earnings Before Interest, Tax, and Depreciation and other non-cash items, and as adjusted for acquisition related items.

2 – Includes $8,914 and $11,228 for the three and nine months ended December 31, 2017, respectively, in share-based compensation expense related to acquisition milestones

SOURCE Canopy Growth Corporation

Post by TraderX

Comments are closed.